Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062358 | 1.00 | KIF11 (0.38) | KIF11MAPTKDM4EGAANPSR1 | |
| SCHEMBL5067454 | 1.00 | KIF11 (0.38) | KIF11MAPTKDM4EGAANPSR1 | |
| SCHEMBL4317700 | 0.85 | HIF1A (0.35) | MAPTKDM4EKMT2APDE1CPOLB | |
| SCHEMBL4317698 | 0.85 | HIF1A (0.35) | MAPTKDM4EKMT2APDE1CPOLB | |
| SCHEMBL4288291 | 0.85 | KIF11 (0.42) | KIF11KDM4EPDE1C | |
| SCHEMBL4317703 | 0.85 | HIF1A (0.35) | MAPTKDM4EKMT2APDE1CPOLB | |
| SCHEMBL5504060 | 0.82 | KIF11 (0.33) | KIF11KMT2AERCC1ERCC5FEN1 | |
| SCHEMBL5058380 | 0.78 | KIF11 (0.53) | KIF11 | |
| SCHEMBL5065963 | 0.78 | KIF11 (0.53) | KIF11 | |
| SCHEMBL5065968 | 0.78 | KIF11 (0.53) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-05-01 | — | — | US | disclosed |
| EP-1856128-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078574-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080102068-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | KIF11 9/4885MAPT 193/4885KDM4E 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.